Demand for 5,000L single-use bioreactors is on the rise among biopharma manufacturers. Here’s why.
When scaling biologics from clinical to commercial production, biopharma companies face a difficult choice: invest in inflexible 10,000-15,000L stainless-steel systems that lock you into fixed capacity, or scale out with multiple 2,000L single-use bioreactors that increase complexity and costs. Both options waste resources—either through unused capacity or operational inefficiency.
The 5,000L single-use bioreactor offers an ideal middle ground. It bridges the gap between small-scale flexibility and commercial-scale capacity, offering the agility to scale up or down as market demand shifts while eliminating the cleaning validation, changeover delays and capital commitment of stainless steel. For the 80% of biologics requiring less than 750 kg/year production, the 5,000L sweet spot matches actual market needs without over- or under-investing in capacity.
Download the white paper to discover:
- Why volatile biopharma markets demand manufacturing flexibility that stainless steel can’t provide
- How 5,000L single-use bioreactors deliver superior economics for products in the 30-150 kg/year demand range
- Real-world scale-up data showing consistent performance from 50L to 5,000L across multiple molecules
- How DynaDrive’s 20:1 turndown ratio and enhanced mass transfer support both early clinical trials and commercial manufacturing
Offered Free by: Thermo Fisher Scientific
See All Resources from: Thermo Fisher Scientific
